Eli Lilly Will Start Selling Cialis Impotency Pill in Japan (Japan)
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly is now selling its Cialis impotency pill in Japan, and has increased its sales force in Japan by 100 to 900 in April. The drug firm's goal is to move from its current spot of 26th to become one of the 20 largest drugmakers in Japan by 2010. "Cialis plays an important role not just in its total sales, but it's also important in terms of capability building," says Newton Crenshaw, president of Eli Lilly's Japanese unit. "We are working hard to expand our efforts to the GP and small-clinic market." Drug sales increased in 2005 the most in 14 years, spurred by the nation's aging population, according to a PricewaterhouseCoopers report. Lilly estimates about 15 billion yen worth of treatments for erectile dysfunction are imported directly by Japanese users each year. Lilly's Japan unit increased revenue by 7 percent to 82.2 billion yen in the year ended Dec. 31, driven by an 11 percent jump in sales of the Zyprexa schizophrenia medicine. (Click here for more - May Require Free Registration
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.